Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
Corporate Policy
Arrowhead is taking the following actions aimed at limiting the spread of COVID-19:
- Providing employees with flexibility around work schedules and recommending that they work from home, to the extent feasible and appropriate;
- Restricting all but the most essential business-related travel;
- Implementing a temporary easing of paid time off policies for any employee and/or family member illnesses and requiring ill employees to remain home for an extended time after symptoms subside;
- Restricting non-employee access to Arrowhead facilities; and
- Enhanced facility hygiene practices including increasing the frequency with which high touch surfaces are cleaned
Clinical Trials
For clinical trials of Arrowhead’s investigational medicines, the company is monitoring each program individually to determine if changes or accommodations are necessary. The COVID-19 pandemic is rapidly evolving, so Arrowhead will continue to assess the impacts, if any. The current status of each wholly-owned clinical program is as follows:
ARO-AAT for the Treatment of Alpha-1 Liver Disease
- Patients already enrolled in SEQUOIA (AROAAT2001) or AROAAT2002 will continue in the study as per the protocol. Options including home healthcare visits, where available, or the utilization of local laboratories, as needed, to facilitate compliance with the study schedule of assessments.
-
Centers for Disease Control and Prevention (CDC ) information related to COVID-19 infection indicates that older adults and those with chronic lung disease are at increased risk of developing severe illness.CDC also recommends avoidance of non-essential travel and, in general, avoiding exposure to infected individuals. Based on these recommendations, Arrowhead is pausing new patient screening for at least a 4-week period in the SEQUOIA and AROAAT2002 studies. - Arrowhead will continue working with new clinical sites to complete the startup process. Clinical sites are encouraged to continue pre-screen efforts to identify eligible patients in preparation for resuming screening efforts.
ARO-APOC3 for the Treatment of Hypertriglyceridemia
- No change to plans or studies
ARO-ANG3 for the Treatment of Dyslipidemia
- No change to plans or studies
ARO-HSD for the Treatment of Alcohol Related and Nonalcohol Related Liver Diseases
- No change to plans or studies
ARO-HIF2 for the Treatment of Clear Cell Renal Cell Carcinoma
- No change to plans or studies
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005752/en/
626-304-3400
ir@arrowheadpharma.com
Investors and Media:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Source: